We are delighted to announce that Mathys & Squire is a Gold sponsor of Life Sciences Patent Network (LSPN) Spring 2026 for the second year running. The event is taking place on the 29th and 30th of April in Boston, Massachusetts.
Partners Hazel Ford, Stephen Garner, Philippa Griffin and Alexander Robinson are attending the event, and Philippa and Stephen are presenting on developments in EPO case law relating to claim interpretation. Our team is looking forward to catching up and sharing knowledge with other leading IP attorneys and life science industry experts from around the world.
Hazel Ford has extensive experience in drafting patent applications and prosecuting them globally. She also has experience with EPO opposition and appeal proceedings, and advises multinational clients on all aspects of patent strategy. Her expertise spans various areas, including antibodies, vaccines, genes, proteins, drug formulation, diagnostics and new administration regimes.
Stephen Garner is experienced in drafting, prosecuting and defending patents across a wide range of pharmaceutical technologies, with a particular focus on those which span the chemical and biological fields. Stephen manages the prosecution of a number of significant global patent portfolios and European SPC portfolios, and regularly advises on SPC matters and EPO oppositions.
Philippa Griffin has a substantial prosecution, opposition, and appeal practice before the EPO, and she is responsible for the coordination and strategic management of complex worldwide patent portfolios covering commercially significant products. She handles inventions in a range of technical areas, including antibodies and immunology, synthetic biology, nucleic acid-based therapies, engineered enzymes, and cardiac diagnostics.
Alexander Robinson has significant experience in contentious inter partes proceedings before the EPO’s Opposition Division and Boards of Appeal. He also manages the prosecution of global patent portfolios relating to authorised medicinal products and drug candidates currently in advanced clinical trials, meaning his practice also extends to SPCs and associated regulatory matters. His work has a particular focus on small molecule pharmaceuticals, antibody-drug conjugates, enzymes, protein production techniques, dosage regimens, dosage forms, biomarkers and diagnostic techniques.
Please reach out to our team if you are interested in arranging a meeting.
For more information on the event, visit the website here.
Contact our team
Hazel Ford – Partner | [email protected]
Stephen Garner – Partner | [email protected]
Philippa Griffin – Partner | [email protected]
Alexander Robinson – Partner | [email protected]
